Category REGENERATIVE MEDICINE

PIER MARIA FORNASARI
2019-08-09

Centers for Medicare & Medicaid Services (CMS) Make CAR T-Cell Cancer Therapy Available to Medicare Beneficiaries Nationwide

Decision ensures consistency in access to the innovative new cancer therapy, and CMS is working closely with sister agencies to monitor outcomes for patients receiving the therapy Today the Centers for Medicare & Medicaid Services (CMS), under the leadership of President Trump and Secretary Azar, finalized the decision to cover FDA-approved Chimeric Antigen Receptor T-cell, or “CAR

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-08-07

Industrial Biotechnology: To What Extent Is Responsible Innovation on the Agenda?

The UK Industrial Biotechnology (IB) Strategy presents a consistent plan to develop the IB sector but fails to endorse an innovation process that allows for input from multiple publics. This could be disadvantageous for the bioeconomy: there are notable cases where negligence to address societal dimensions has caused innovation failure. In 2018, the UK Industrial

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-08-07

Muscular contribution to adolescent idiopathic scoliosis from the perspective of stem cell-based regenerative medicine.

Source https://www.liebertpub.com/doi/pdf/10.1089/scd.2019.0073 Adolescent idiopathic scoliosis (AIS) is a relatively frequent disease within a range 0.5-5.0% of population, with higher frequency in females. While a resultant spinal deformity is usually medically benign condition, it produces far going psychosocial consequences, which warrants attention. The etiology of AIS is unknown and current therapeutic approaches are symptomatic only, and

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-08-05

Car-T: the first agreement for new therapies, based on actual results, is ready. Martini (Ex Dg Aifa): “A new negotiation model that puts Italy at the forefront”

The first agreement (with Novartis) for therapies that allow to reprogram some cells of the patient (the T lymphocytes), in order to make them able, once reinfused, to recognize and target the tumors, is approved by the CPR and CTS of Aifa. Now the agreement will have to be ratified by the AIFA Board and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2019-08-03

University of Minnesota achieves transplant in monkeys without long-term immune-fighting drugs

The technique could greatly increase the number and safety of organ transplants.  University of Minnesota researchers are reporting a breakthrough in what has long been viewed as a holy grail in the field of organ transplantation — success without the permanent need for immunosuppressive drugs. Their technique could greatly increase the number and safety of

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2019-08-02

Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States

There are currently hundreds of businesses across the United States offering direct-to-consumer stem cell treatments that have not been through regulatory approval by the Food and Drug Administration (FDA). Here, we provide a detailed characterization of nearly 170 stem cell businesses operating in the Southwest United States. We draw specific attention to two as-yet understudied

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-08-02

Injectable ‘bone spackling’: A cell therapy approach to heal complex fractures

Large, complex bone wounds are hard for doctors and patients alike to contend with. They often require grafts and multiple surgeries. Jan Stegemann, a University of Michigan professor of biomedical engineering, is reprogramming adult cells from bonemarrow so that they can be injected directly into a wound and grow into bone. The marrow-derived cells are known as progenitor cells, a type

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-08-02

Just Released: Q2 2019 Regenerative Medicine Sector Report

Year-to-Date Metrics and Trends for the Gene Therapy, Cell Therapy, Tissue Engineering,and Broader Regenerative Medicine Sector. ARM today released its most recent quarterly sector report, offering an in-depth look at the gene therapy, cell therapy, tissue engineering, and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2019. By further curating information provided

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2019-07-31

Mesenchymal Stem Cells for Perianal Crohn’s Disease

Perianal fistulizing Crohn’s disease (PFCD) is associated with significant morbidity and might negatively impact the quality of life of CD patients. In the last two decades, the management of PFCD has evolved in terms of the multidisciplinary approach involving gastroenterologists and colorectal surgeons. However, the highest fistula healing rates, even combining surgical and anti-TNF agents,

Read More

No Comments InCELL THERAPY